Lite Strategy, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Lite Strategy, Inc. (LITS) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$31.84 million for the 12-month period ending 2023-06-30, per its 10-K filed 2023-09-26.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2023-09-26
- Lite Strategy, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-06-30 was -$10.03M.
- Lite Strategy, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2023-03-31 was -$15.44M.
- Lite Strategy, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2022-12-31 was $10.25M.
- Lite Strategy, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2022-09-30 was -$16.62M.
- Lite Strategy, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$31.84M.
- Lite Strategy, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$62.50M.
- Lite Strategy, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$68.71M.
- Lite Strategy, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$47.17M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-06-30 | -$10.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-26 | -$25.47M derived: sum of 2 quarters · filed 2023-09-26 | -$15.21M derived: sum of 3 quarters · filed 2023-09-26 | -$31.84M 10-K · filed 2023-09-26 | ||||
| 2023-03-31 | -$15.44M 10-Q · filed 2023-05-11 | -$5.18M derived: sum of 2 quarters · filed 2023-05-11 | -$21.81M 10-Q · filed 2023-05-11 | -$37.87M derived: sum of 4 quarters · filed 2023-09-26 | ||||
| 2022-12-31 | $10.25M 10-Q · filed 2023-02-09 | -$6.37M 10-Q · filed 2023-02-09 | -$22.43M derived: sum of 3 quarters · filed 2023-09-26 | -$31.16M derived: sum of 4 quarters · filed 2023-09-26 | ||||
| 2022-09-30 | -$16.62M 10-Q · filed 2022-11-14 | -$32.69M derived: sum of 2 quarters · filed 2023-09-26 | -$41.41M derived: sum of 3 quarters · filed 2023-09-26 | -$59.03M derived: sum of 4 quarters · filed 2023-09-26 | ||||
| 2022-06-30 | -$16.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-26 | -$24.79M derived: sum of 2 quarters · filed 2023-09-26 | -$42.40M derived: sum of 3 quarters · filed 2023-09-26 | -$62.50M 10-K · filed 2023-09-26 | ||||
| 2022-03-31 | -$8.72M 10-Q · filed 2023-05-11 | -$26.34M derived: sum of 2 quarters · filed 2023-05-11 | -$46.44M 10-Q · filed 2023-05-11 | -$61.90M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$17.61M 10-Q · filed 2023-02-09 | -$11.22M 10-Q · filed 2022-02-10 | -$37.71M 10-Q · filed 2023-02-09 | -$25.69M 10-Q · filed 2022-02-10 | -$53.18M derived: sum of 3 quarters · filed 2023-02-09 | -$78.80M derived: sum of 4 quarters · filed 2023-02-09 | ||
| 2021-09-30 | -$20.10M 10-Q · filed 2022-11-14 | -$14.47M 10-Q · filed 2021-11-10 | -$35.56M derived: sum of 2 quarters · filed 2022-11-14 | -$61.18M derived: sum of 3 quarters · filed 2022-11-14 | -$76.29M derived: sum of 4 quarters · filed 2022-11-14 | |||
| 2021-06-30 | -$15.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | -$41.09M derived: sum of 2 quarters · filed 2022-09-08 | -$56.20M derived: sum of 3 quarters · filed 2022-09-08 | -$68.71M 10-K · filed 2022-09-08 | -$77.97M 10-K · filed 2021-09-02 | |||
| 2021-03-31 | -$25.62M 10-Q · filed 2022-05-23 | -$31.31M 10-Q · filed 2021-05-06 | -$40.73M derived: sum of 2 quarters · filed 2022-05-23 | -$53.24M 10-Q · filed 2022-05-23 | -$65.17M 10-Q · filed 2021-05-06 | -$72.88M derived: sum of 4 quarters · filed 2022-09-08 | ||
| 2020-12-31 | -$15.11M 10-Q/A · filed 2022-05-23 | -$18.54M 10-Q · filed 2021-02-04 | -$27.62M 10-Q/A · filed 2022-05-23 | -$33.85M 10-Q · filed 2021-02-04 | -$47.25M derived: sum of 3 quarters · filed 2022-09-08 | -$51.58M derived: sum of 4 quarters · filed 2022-09-08 | ||
| 2020-09-30 | -$12.51M 10-Q/A · filed 2022-05-23 | -$15.32M 10-Q · filed 2020-11-10 | -$32.15M derived: sum of 2 quarters · filed 2022-09-08 | -$36.47M derived: sum of 3 quarters · filed 2022-09-08 | -$56.69M derived: sum of 4 quarters · filed 2022-09-08 | |||
| 2020-06-30 | -$19.63M derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-08 | -$23.96M derived: sum of 2 quarters · filed 2022-09-08 | -$44.18M derived: sum of 3 quarters · filed 2022-09-08 | -$47.17M 10-K · filed 2022-09-08 | -$46.02M 10-K · filed 2020-09-09 | |||
| 2020-03-31 | -$4.33M 10-Q · filed 2021-05-06 | -$24.55M derived: sum of 2 quarters · filed 2021-05-06 | -$27.54M 10-Q · filed 2021-05-06 | -$38.84M derived: sum of 4 quarters · filed 2022-05-23 | ||||
| 2019-12-31 | -$20.22M 10-Q · filed 2021-02-04 | -$23.21M 10-Q · filed 2021-02-04 | -$34.52M derived: sum of 3 quarters · filed 2022-05-23 | -$51.87M derived: sum of 4 quarters · filed 2022-05-23 | ||||
| 2019-09-30 | -$2.99M 10-Q · filed 2020-11-10 | -$14.30M derived: sum of 2 quarters · filed 2022-05-23 | -$31.65M derived: sum of 3 quarters · filed 2022-05-23 | -$43.06M derived: sum of 4 quarters · filed 2022-05-23 | ||||
| 2019-06-30 | -$11.30M derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-05-23 | -$28.66M derived: sum of 2 quarters · filed 2022-05-23 | -$40.07M derived: sum of 3 quarters · filed 2022-05-23 | -$54.61M 10-K/A · filed 2022-05-23 | ||||
| 2019-03-31 | -$17.36M 10-Q · filed 2020-05-07 | -$28.77M derived: sum of 2 quarters · filed 2020-05-07 | -$43.31M 10-Q · filed 2020-05-07 | |||||
| 2018-12-31 | -$11.41M 10-Q · filed 2020-02-06 | -$25.95M 10-Q · filed 2020-02-06 | ||||||
| 2018-06-30 | -$19.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-09 | -$25.20M derived: sum of 2 quarters · filed 2020-09-09 | -$31.28M derived: sum of 3 quarters · filed 2020-09-09 | -$40.07M 10-K · filed 2020-09-09 | ||||
| 2018-03-31 | -$5.95M 10-Q · filed 2019-05-09 | -$12.03M derived: sum of 2 quarters · filed 2019-05-09 | -$20.82M 10-Q · filed 2019-05-09 | |||||
| 2017-12-31 | -$6.08M 10-Q · filed 2019-02-07 | -$14.87M 10-Q · filed 2019-02-07 | ||||||
| 2017-06-30 | $2.67M 10-K · filed 2019-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |